RENO, Nev., June 15, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. (Pink Sheets:MTNU) references new research which suggests that rather than protecting women from breast cancer, long term daily use of Ibuprofen increases the risk of breast tumors. This study, published yesterday in the Journal of the National Cancer Institute, cites a study involving "1,500 women who have been taking Ibuprofen for 5 years or more, are at an increased risk of breast cancer by 51%."
"These results ought to scare the life out of arthritic patients on Ibuprofen," says Dr. Martin, Director of Research and Product Development at Martin Nutraceuticals Inc. "With the use of Celebrex and Vioxx also causing great concern, the market is looking for a safe alternative that is highly effective. The answer is found in Arthrizyme(tm), the all natural patent-pending systemic oral enzyme formula developed by Martin Nutraceuticals Inc."
Arthrizyme(tm) is an all-natural unique blend of system enzymes designed to provide superior anti-inflammatory benefits, by breaking down harmful protein and facilitating its removal from the body. Martin Nutraceuticals Arthrizyme(tm) has also shown to have an affect on improving blood flow and regulating the immune system, resulting in a faster healing process.
The arthritis market is an industry that is surpassing a billion dollars annually in sales. It is estimated that 1 out of 3 Americans are suffering with Arthritis.
"This study reinforces that the arthritic suffers are ready for a safe alternative to potentially harmful and deadly drugs. They are ready for Arthrizyme(tm) and we are preparing ourselves to offer it to them," states Dr. Martin.
Arthrizyme(tm) will be available on retail shelves shortly.
Forward Looking Statements
This release includes forward-looking statements and projections, made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release, including, without limitation, the ability to implement and achieve our objectives in the long-range plan; actions by the credit rating agencies; the successful close of our financing transactions; our ability to divest of certain assets; inability to realize anticipated synergies and cost savings associated with restructurings and divestitures on a timely basis; the uncertainties associated with governmental regulation; the uncertainties associated with the outcome of governmental investigations; the outcome of pending litigation including shareholder derivative and class actions; difficulty in integration of the operations of previously acquired companies, and competition. While the company makes these statements and projections in good faith, neither the company nor its management can guarantee that anticipated future results will be achieved. The company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new information, future events, or otherwise.